Literature DB >> 19100317

Gene expression analysis of terminal differentiation of human melanoma cells highlights global reductions in cell cycle-associated genes.

Kim Mai Huynh1, Gyoungmi Kim, Dong-Joon Kim, Suk-Jin Yang, Seong-min Park, Young-Il Yeom, Paul B Fisher, Dongchul Kang.   

Abstract

Defects in differentiation are frequently observed in cancer cells. By appropriate treatment specific tumor cell types can be induced to terminally differentiate. Metastatic HO-1 human melanoma cells treated with IFN-beta plus mezerein (MEZ) undergo irreversible growth arrest and terminal differentiation followed by apoptosis. In order to define the molecular changes associated with this process, changes in gene expression were analyzed by cDNA microarray hybridization and by semi-quantitative and quantitative RT-PCRs of representative 44 genes. The expression of 210 genes was changed more than two-fold at either 8 or 24 h post-treatment (166 up and 44 down). Major biological processes associated with the up-regulated genes were response to endogenous/exogenous stimuli (38%), cell proliferation (13%), cell death (16%) and development (30%). Approximately 34% of the down-regulated genes were associated with cell cycle, 9% in DNA replication and 11% in chromosome organization, respectively. Suppression of cell cycle associated genes appeared to directly correlate with growth arrest observed in the terminal differentiation process. Expression of Calpain 3 (CAPN3) variant 6 was suppressed by the combined treatment and maintained high in various melanoma cell lines. However, over-expression of the CAPN3 did not significantly affect growth kinetics and cell viability, suggesting that up-regulation of CAPN3 alone may not be a causative, but an associated change with melanoma development. This analysis provides further insights into the spectrum of up-regulated and the first detailed investigation of down-regulated gene changes associated with and potentially causative of induction of loss of proliferative capacity and terminal differentiation in human melanoma cells.

Entities:  

Mesh:

Year:  2008        PMID: 19100317     DOI: 10.1016/j.gene.2008.11.013

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  Calpain3 is expressed in a proteolitically active form in papillomavirus-associated urothelial tumors of the urinary bladder in cattle.

Authors:  Sante Roperto; Roberta De Tullio; Cinzia Raso; Roberto Stifanese; Valeria Russo; Marco Gaspari; Giuseppe Borzacchiello; Monica Averna; Orlando Paciello; Gianni Cuda; Franco Roperto
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

2.  Calpain-3 impairs cell proliferation and stimulates oxidative stress-mediated cell death in melanoma cells.

Authors:  Daniele Moretti; Barbara Del Bello; Giulia Allavena; Alessandro Corti; Cinzia Signorini; Emilia Maellaro
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

3.  Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms.

Authors:  Yusha Xiao; Rahmathullah Mohamed Najeeb; Dong Ma; Kang Yang; Qiu Zhong; Quanyan Liu
Journal:  J Exp Clin Cancer Res       Date:  2019-11-08

Review 4.  CAPN3: A muscle‑specific calpain with an important role in the pathogenesis of diseases (Review).

Authors:  Lin Chen; Fajuan Tang; Hu Gao; Xiaoyan Zhang; Xihong Li; Dongqiong Xiao
Journal:  Int J Mol Med       Date:  2021-09-22       Impact factor: 4.101

Review 5.  Targeting tumor invasion: the roles of MDA-9/Syntenin.

Authors:  Timothy P Kegelman; Swadesh K Das; Luni Emdad; Bin Hu; Mitchell E Menezes; Praveen Bhoopathi; Xiang-Yang Wang; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Ther Targets       Date:  2014-09-15       Impact factor: 6.902

6.  Identification of genes potentially regulated by human polynucleotide phosphorylase (hPNPase old-35) using melanoma as a model.

Authors:  Upneet K Sokhi; Manny D Bacolod; Santanu Dasgupta; Luni Emdad; Swadesh K Das; Catherine I Dumur; Michael F Miles; Devanand Sarkar; Paul B Fisher
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.